{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-23-018785","form_type":"8-K","ticker":"RVMD","cik":"0001628171","company_name":"Revolution Medicines, Inc.","filed_at":"2023-05-08T23:59:59+00:00","discovered_at":"2026-05-14T18:03:39.731907+00:00","generated_at":"2026-06-15T13:28:18.190254+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Revolution Medicines Q1 net loss $68.1M, cash $909.8M; guides FY net loss $360-400M","bullets":["Net loss of $68.1M for Q1 2023 vs $57.6M loss in Q1 2022; R&D expenses $68.9M (up 22% YoY).","Cash $909.8M as of March 31, 2023, up from $644.9M in Dec 2022, boosted by $345M public offering in March.","Updated FY 2023 GAAP net loss guidance to $360-$400M; cash runway projected into 2025.","Appointed Wei Lin, M.D., as CMO; also hired senior VPs for commercial, regulatory, CMC.","Clinical progress: RMC-6236 data update mid-2023; RMC-6291 preliminary report H2 2023; RMC-9805 first patient dosing mid-2023."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-23-018785","json":"https://secwatch.observer/filing/0000950170-23-018785.json","markdown":"https://secwatch.observer/filing/0000950170-23-018785.md","text":"https://secwatch.observer/filing/0000950170-23-018785.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1628171/000095017023018785/0000950170-23-018785-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1628171/000095017023018785/rvmd-20230508.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-15T13:28:18.190254+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"ace8c1b4c920fabd282e13e81681a7c0f7544126","claim":"Revolution Medicines, Inc. reported financial results for the quarter ended March 31, 2023.","evidence_excerpt":"On May 8, 2023, Revolution Medicines, Inc. (the “Company”) announced its financial results for the quarter ended March 31, 2023.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1628171/000095017023018785/0000950170-23-018785-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the quarter ended March 31, 2023"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}